Early Microglial Changes Associated with Diabetic Retinopathy in Rats with Streptozotocin-Induced Diabetes.

J Diabetes Res

Department of Ophthalmology and Visual Science, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

Published: March 2022


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Although morphological changes in microglia have been reported to be associated with diabetic retinopathy, little is known about the early changes in the microglia and macrophages during the progression of this condition. The present study was aimed at characterizing retinal microglial activation in the early stages of experimental diabetic retinopathy. Toward this end, a model of diabetic retinopathy was generated by intraperitoneally injecting male Sprague-Dawley rats with streptozotocin. No apparent histological changes were observed during the early stages of experimental diabetic retinopathy. However, at 4 to 16 weeks after the onset of diabetes, the retinas from diabetic rats exhibited higher density of microglia than those from age-matched normal controls, with microglial density peaking at 12 weeks. In particular, the proportion of the activated microglia increased significantly in the diabetic rats, specifically in the nerve fiber and ganglion cell layers, whereas it decreased in the inner plexiform layer within 12 weeks. Furthermore, the resident retinal microglial cells were activated immediately after diabetes induction, peaked at 12 weeks, and remained for up to 16 weeks after disease onset. Thus, experimental diabetic retinopathy causes gradual hypoxia and neuroinflammation, followed by the activation of microglia and the migration of macrophages. The distribution and density of retinal microglial activation changed typically with the progression of the disease in early-stage diabetic rats.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674052PMC
http://dx.doi.org/10.1155/2021/4920937DOI Listing

Publication Analysis

Top Keywords

diabetic retinopathy
24
retinal microglial
12
experimental diabetic
12
diabetic rats
12
diabetic
9
associated diabetic
8
changes microglia
8
microglial activation
8
early stages
8
stages experimental
8

Similar Publications

Diabetic retinopathy (DR) remains a leading cause of preventable blindness worldwide, with the affected population projected to reach 270 million by 2045. Our study analyzed 2 434 interventional trials registered between 2007 and 2024 in the Informa Pharma Intelligence database and found that anti-VEGF agents dominate the therapeutic landscape-bevacizumab represents 24.0 % of studies, ranibizumab 15.

View Article and Find Full Text PDF

Purpose: To evaluate macular vessel density using clinical parameters in patients with type 2 diabetes mellitus (DM) without retinopathy.

Patients And Methods: This cross-sectional study enrolled 32 participants (63 eyes) aged 40-60 years who met the inclusion criteria. Group 1 included 32 eyes of type 2 DM, whereas the rest had no DM.

View Article and Find Full Text PDF

Organoids: their emerging essential role in pathological mechanisms and drug discovery of diabetes and its complications.

Front Pharmacol

August 2025

State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Beijing, China.

Diabetes mellitus is a metabolic disease with a high global prevalence, which affects blood vessels throughout the entire body. As the disease progresses, it often leads to complications, including diabetic retinopathy and nephropathy. Currently, in addition to traditional cellular and animal models, more and more organoid models have been used in the study of diabetes and have broad application prospects in the field of pharmacological research.

View Article and Find Full Text PDF

Background: Artificial intelligence (AI) algorithms offer an effective solution to alleviate the burden of diabetic retinopathy (DR) screening in public health settings. However, there are challenges in translating diagnostic performance and its application when deployed in real-world conditions.

Objective: This study aimed to assess the technical feasibility of integration and diagnostic performance of validated DR screening (DRS) AI algorithms in real-world outpatient public health settings.

View Article and Find Full Text PDF

Dapagliflozin improves diabetic retinopathy in mice by inhibiting LAMA1 and regulating the PI3K/AKT signaling pathway.

Biochem Biophys Res Commun

September 2025

Department of Ophthalmology, Hebei Medical University, NO. 361 Zhongshan East Road, Changan District, Shijiazhuang City, Hebei Province, China; Department of Ophthalmology, Hebei General Hospital, NO. 348 Heping West Road, Xinhua District, Shijiazhuang City, Hebei Province, China. Electronic address

Diabetic retinopathy (DR) is among the most prevalent complications linked to advanced diabetes. Capillary Basement membrane (CBM) thickening is an early clinical manifestation in DR, and Laminin α 1 (LAMA1) is one of the main extracellular matrix components involved in CBM formation. Dapagliflozin (DAPA) has demonstrated efficacy in ameliorating DR.

View Article and Find Full Text PDF